About US
Contact us
-
With FDA panel nod, ThromboGenics closer to first potential drugThromboGenics came closer to having its first approved drug on the U.S. market, gaining an FDA advisory committee recommendation for its lead drug candidate, ocriplasmin, for combatting vision-impairi2012/7/30
-
Merck earnings down, but strength surprises Wall StreetSales of Merck's ($MRK) asthma drug Singulair were up 5.7%. Its diabetes drug Januvia grew 36% to $1.06 billion, and sales of its other key diabetes treatment, Janumet, climbed 28% to $411 million.2012/7/27
-
Amarin prepared for aggressive launch of billion-dollar fish oilYou can buy a twin-pack of Omega 3 fish oil at Walmart for six bucks. Yet Amarin($AMRN) has been so certain that its prescription fish oil will have huge demand that it has spent the last 18 months ge2012/7/27
-
Cancer drugs lift Roche sales as charges slash earningsTwo words explain why Roche might well be the envy of Big Pharma: cancer drugs. The company ($RHHBY) posted sales growth, despite European pricing pressures, to $22.61 billion. Drug revenues beat fore2012/7/26
-
Generics drag AZ sales down by $1.35BAstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage. It fell over the patent cliff at the e2012/7/26
-
FDA to Congress: Agency not the cause of drug shortagesWhen it comes to drug shortages, the FDA says it is not the problem. It is part of the solution. That is what the agency says in a 9-page letter, with point-by-point refutations, to the ranking membe2012/7/25
-
Generics take a billion-dollar bite from Bristol-Myers salesIf today's pharma sales reports look grim, none is so grim as Bristol-Myers Squibb's ($BMY). The company's loss of exclusivity on its top-selling drug Plavix helped push U.S. sales down by 27%. The lo2012/7/25
-
Search for cheap prices sets stage for more counterfeit drugsAs Canadian online pharmacies morphed to protect their business model, they also became more vulnerable to counterfeits from places such as India and Turkey, where they turned for cheap supplies. That2012/7/24
-
J&J appeals $1.2B Risperdal marketing fineJohnson & Johnson has officially protested a $1.2 billion fine for mismarketing a blockbuster antipsychotic. In its ongoing fight against Risperdal marketing allegations, the company ($JNJ) app2012/7/24
-
Did anemia drug giants game the system to rake in billions?Amgen's big-selling anemia drugs were first brought in for questioning a few years ago. Studies and side-effect reports cast doubt on their safety. The FDA started a review. Then, in 2007, FDA slapped2012/7/23